About Centromere protein F
Centromere protein F (CENPF) is a protein
from Homo sapiens identified by UniProt accession
P49454, 3114 residues long.
MolForge cross-references it against 0 known binders and
207 disease associations.
Target properties
| Protein name | Centromere protein F |
|---|
| UniProt accession | P49454 |
|---|
| Gene | CENPF |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3114 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (207)
Diseases linked to this target (Open Targets).
- stromme syndrome · score 0.82
- Neurodevelopmental delay · score 0.43
- neurodegenerative disease · score 0.39
- microcephalic primordial dwarfism · score 0.37
- YKL40 measurement · score 0.30
- inflammatory biomarker measurement · score 0.30
- primary ciliary dyskinesia · score 0.27
- cystinuria · score 0.27
- ovarian cancer · score 0.23
- low grade glioma · score 0.23
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3114 residues)
MSWALEEWKE GLPTRALQKI QELEGQLDKL KKEKQQRQFQ LDSLEAALQK QKQKVENEKT EGTNLKRENQ RLMEICESLE KTKQKISHEL QVKESQVNFQ EGQLNSGKKQ IEKLEQELKR CKSELERSQQ AAQSADVSLN PCNTPQKIFT TPLTPSQYYS GSKYEDLKEK YNKEVEERKR LEAEVKALQA KKASQTLPQA TMNHRDIARH QASSSVFSWQ QEKTPSHLSS NSQRTPIRRD FSASYFSGEQ EVTPSRSTLQ IGKRDANSSF FDNSSSPHLL DQLKAQNQEL RNKINELELR LQGHEKEMKG QVNKFQELQL QLEKAKVELI EKEKVLNKCR DELVRTTAQY DQASTKYTAL EQKLKKLTED LSCQRQNAES ARCSLEQKIK EKEKEFQEEL SRQQRSFQTL DQECIQMKAR LTQELQQAKN MHNVLQAELD KLTSVKQQLE NNLEEFKQKL CRAEQAFQAS QIKENELRRS MEEMKKENNL LKSHSEQKAR EVCHLEAELK NIKQCLNQSQ NFAEEMKAKN TSQETMLRDL QEKINQQENS LTLEKLKLAV ADLEKQRDCS QDLLKKREHH IEQLNDKLSK TEKESKALLS ALELKKKEYE ELKEEKTLFS CWKSENEKLL TQMESEKENL QSKINHLETC LKTQQIKSHE YNERVRTLEM DRENLSVEIR NLHNVLDSKS VEVETQKLAY MELQQKAEFS DQKHQKEIEN MCLKTSQLTG QVEDLEHKLQ LLSNEIMDKD RCYQDLHAEY ESLRDLLKSK DASLVTNEDH QRSLLAFDQQ PAMHHSFANI IGEQGSMPSE RSECRLEADQ SPKNSAILQN RVDSLEFSLE SQKQMNSDLQ KQCEELVQIK GEIEENLMKA EQMHQSFVAE TSQRISKLQE DTSAHQNVVA ETLSALENKE KELQLLNDKV ETEQAEIQEL KKSNHLLEDS LKELQLLSET LSLEKKEMSS IISLNKREIE ELTQENGTLK EINASLNQEK MNLIQKSESF ANYIDEREKS ISELSDQYKQ EKLILLQRCE ETGNAYEDLS QKYKAAQEKN SKLECLLNEC TSLCENRKNE LEQLKEAFAK EHQEFLTKLA FAEERNQNLM LELETVQQAL RSEMTDNQNN SKSEAGGLKQ EIMTLKEEQN KMQKEVNDLL QENEQLMKVM KTKHECQNLE SEPIRNSVKE RESERNQCNF KPQMDLEVKE ISLDSYNAQL VQLEAMLRNK ELKLQESEKE KECLQHELQT IRGDLETSNL QDMQSQEISG LKDCEIDAEE KYISGPHELS TSQNDNAHLQ CSLQTTMNKL NELEKICEIL QAEKYELVTE LNDSRSECIT ATRKMAEEVG KLLNEVKILN DDSGLLHGEL VEDIPGGEFG EQPNEQHPVS LAPLDESNSY EHLTLSDKEV QMHFAELQEK FLSLQSEHKI LHDQHCQMSS KMSELQTYVD SLKAENLVLS TNLRNFQGDL VKEMQLGLEE GLVPSLSSSC VPDSSSLSSL GDSSFYRALL EQTGDMSLLS NLEGAVSANQ CSVDEVFCSS LQEENLTRKE TPSAPAKGVE ELESLCEVYR QSLEKLEEKM ESQGIMKNKE IQELEQLLSS ERQELDCLRK QYLSENEQWQ QKLTSVTLEM ESKLAAEKKQ TEQLSLELEV ARLQLQGLDL SSRSLLGIDT EDAIQGRNES CDISKEHTSE TTERTPKHDV HQICDKDAQQ DLNLDIEKIT ETGAVKPTGE CSGEQSPDTN YEPPGEDKTQ GSSECISELS FSGPNALVPM DFLGNQEDIH NLQLRVKETS NENLRLLHVI EDRDRKVESL LNEMKELDSK LHLQEVQLMT KIEACIELEK IVGELKKENS DLSEKLEYFS CDHQELLQRV ETSEGLNSDL EMHADKSSRE DIGDNVAKVN DSWKERFLDV ENELSRIRSE KASIEHEALY LEADLEVVQT EKLCLEKDNE NKQKVIVCLE EELSVVTSER NQLRGELDTM SKKTTALDQL SEKMKEKTQE LESHQSECLH CIQVAEAEVK EKTELLQTLS SDVSELLKDK THLQEKLQSL EKDSQALSLT KCELENQIAQ LNKEKELLVK ESESLQARLS ESDYEKLNVS KALEAALVEK GEFALRLSST QEEVHQLRRG IEKLRVRIEA DEKKQLHIAE KLKEREREND SLKDKVENLE RELQMSEENQ ELVILDAENS KAEVETLKTQ IEEMARSLKV FELDLVTLRS EKENLTKQIQ EKQGQLSELD KLLSSFKSLL EEKEQAEIQI KEESKTAVEM LQNQLKELNE AVAALCGDQE IMKATEQSLD PPIEEEHQLR NSIEKLRARL EADEKKQLCV LQQLKESEHH ADLLKGRVEN LERELEIART NQEHAALEAE NSKGEVETLK AKIEGMTQSL RGLELDVVTI RSEKENLTNE LQKEQERISE LEIINSSFEN ILQEKEQEKV QMKEKSSTAM EMLQTQLKEL NERVAALHND QEACKAKEQN LSSQVECLEL EKAQLLQGLD EAKNNYIVLQ SSVNGLIQEV EDGKQKLEKK DEEISRLKNQ IQDQEQLVSK LSQVEGEHQL WKEQNLELRN LTVELEQKIQ VLQSKNASLQ DTLEVLQSSY KNLENELELT KMDKMSFVEK VNKMTAKETE LQREMHEMAQ KTAELQEELS GEKNRLAGEL QLLLEEIKSS KDQLKELTLE NSELKKSLDC MHKDQVEKEG KVREEIAEYQ LRLHEAEKKH QALLLDTNKQ YEVEIQTYRE KLTSKEECLS SQKLEIDLLK SSKEELNNSL KATTQILEEL KKTKMDNLKY VNQLKKENER AQGKMKLLIK SCKQLEEEKE ILQKELSQLQ AAQEKQKTGT VMDTKVDELT TEIKELKETL EEKTKEADEY LDKYCSLLIS HEKLEKAKEM LETQVAHLCS QQSKQDSRGS PLLGPVVPGP SPIPSVTEKR LSSGQNKASG KRQRSSGIWE NGRGPTPATP ESFSKKSKKA VMSGIHPAED TEGTEFEPEG LPEVVKKGFA DIPTGKTSPY ILRRTTMATR TSPRLAAQKL ALSPLSLGKE NLAESSKPTA GGSRSQKVKV AQRSPVDSGT ILREPTTKSV PVNNLPERSP TDSPREGLRV KRGRLVPSPK AGLESNGSEN CKVQ
Explore Centromere protein F with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets